171 related articles for article (PubMed ID: 8432223)
1. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity.
Jenney A; Proietto J; O'Dea K; Nankervis A; Traianedes K; D'Embden H
Diabetes Care; 1993 Feb; 16(2):499-502. PubMed ID: 8432223
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
[TBL] [Abstract][Full Text] [Related]
3. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
5. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
Holman RR; Cull CA; Turner RC
Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB
Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
11. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
Josse RG
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with acarbose: results of a Canadian multicentre study.
Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
[TBL] [Abstract][Full Text] [Related]
15. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?
Scott R; Lintott CJ; Zimmet P; Campbell L; Bowen K; Welborn T
Diabetes Res Clin Pract; 1999 Mar; 43(3):179-85. PubMed ID: 10369427
[TBL] [Abstract][Full Text] [Related]
16. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Bayraktar M; Van Thiel DH; Adalar N
Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
[TBL] [Abstract][Full Text] [Related]
17. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
Meneilly GS; Ryan EA; Radziuk J; Lau DC; Yale JF; Morais J; Chiasson JL; Rabasa-Lhoret R; Maheux P; Tessier D; Wolever T; Josse RG; Elahi D
Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
[TBL] [Abstract][Full Text] [Related]
18. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
Costa B; Piñol C
Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
Cusi K; Consoli A; DeFronzo RA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.
Buchanan DR; Collier A; Rodrigues E; Millar AM; Gray RS; Clarke BF
Eur J Clin Pharmacol; 1988; 34(1):51-3. PubMed ID: 3282895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]